Article
Multidisciplinary Sciences
Ji Lei, Maria M. Coronel, Esma S. Yolcu, Hongping Deng, Orlando Grimany-Nuno, Michael D. Hunckler, Vahap Ulker, Zhihong Yang, Kang M. Lee, Alexander Zhang, Hao Luo, Cole W. Peters, Zhongliang Zou, Tao Chen, Zhenjuan Wang, Colleen S. McCoy, Ivy A. Rosales, James F. Markmann, Haval Shirwan, Andres J. Garcia
Summary: We report a strategy of cotransplanting allogeneic islets and streptavidin (SA)-FasL-presenting microgels to the omentum under transient rapamycin monotherapy, which resulted in robust glycemic control, sustained C-peptide levels, and graft survival in diabetic nonhuman primates. This localized immunomodulatory strategy shows translational potential in beta cell replacement for treating type 1 diabetes.
Article
Cardiac & Cardiovascular Systems
Richard C. Daly, Andrew N. Rosenbaum, Joseph A. Dearani, Alfredo L. Clavell, Naveen L. Pereira, Barry A. Boilson, Robert P. Frantz, Atta Behfar, Shannon M. Dunlay, Richard J. Rodeheffer, John A. Schirger, Timucin Taner, Manish J. Gandhi, Julie K. Heimbach, Charles B. Rosen, Brooks S. Edwards, Sudhir S. Kushwaha
Summary: This study demonstrates the successful transplantation using a heart-after-liver transplantation protocol, which provides profound immunologic protection and prevents adverse immunological outcomes in highly sensitized patients requiring combined heart-liver transplantation. The results show near-elimination of donor specific antibodies and minimal rejection episodes, leading to favorable long-term patient and graft outcomes.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
(2021)
Review
Cardiac & Cardiovascular Systems
Maria Generosa Crespo-Leiro, Maria Rosa Costanzo, Finn Gustafsson, Kiran K. Khush, Peter S. Macdonald, Luciano Potena, Josef Stehlik, Andreas Zuckermann, Mandeep R. Mehra
Summary: Heart transplantation faces challenges including limited organ pool, personalized immunosuppressive therapy, and minimizing late complications. Advances such as using hepatitis C-infected donors, expanding donor source, and new preservation techniques have increased organ availability. Mechanical circulatory support has helped patients with advanced heart failure maintain organ function while waiting for a suitable donor match.
EUROPEAN HEART JOURNAL
(2022)
Article
Agriculture, Dairy & Animal Science
G. B. Hall, J. A. Long, L. Susta, B. J. Wood, G. Y. Bedecarrats
Summary: This study tested the effect of removing different proportions of recipient ovarian tissue and using the abdominal air sac membrane as an anchor on transplant attachment rates. The study also evaluated the immune response in the transplants. The results showed that removing the entire recipient ovary can prevent gonadal chimeras, and the use of the abdominal air sac membrane did not affect attachment rates. The high levels of lymphocytes in the transplants indicate a potential tissue rejection.
Article
Immunology
Elena Crespo, Anna Vidal-Alabro, Thomas Jouve, Pere Fontova, Maik Stein, Sonila Mocka, Maria Meneghini, Anett Sefrin, Petra Hruba, Montserrat Goma, Alba Torija, Laura Donadeu, Alex Fava, Josep M. Cruzado, Edoardo Melilli, Francesc Moreso, Ondrej Viklicky, Frederike Bemelman, Petra Reinke, Josep Grinyo, Nuria Lloberas, Oriol Bestard
Summary: This study investigated how functional TAC-CYP3A genetic variants influence the risk of biopsy-proven acute rejection (BPAR) in kidney transplant patients. The results showed that different genetic variants impacted TAC exposure levels and predicted the occurrence of BPAR. Combining genetic variants with other clinical and immunological risk factors may improve the prediction of rejection risk.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Immunology
Praveen Chandrashekhar, Anupma Kaul, Dharmendra Bhaduaria, Narayan Prasad, Manas Behera, Ravi Kushwaha, Manas Patel, Monika Yachha, Aneesh Srivastava
Summary: This study found that the use of Rituximab is not significantly associated with a higher incidence of tuberculosis (TB) in renal transplant patients. The only factor associated with a greater incidence of TB was a higher number of rejection episodes. Treatment of humoral rejections with plasmapheresis in the post-transplant period was also associated with a significantly higher incidence of TB.
TRANSPLANT INFECTIOUS DISEASE
(2022)
Article
Immunology
Xu Lan, Yong-Hao Hu, Xiang Li, De-Jun Kong, Ya-Fei Qin, Hao Wang
Summary: The study demonstrated that oxymatrine (OMT) could protect cardiac allografts by regulating immunotolerant cells. In vitro, OMT inhibited splenocyte proliferation and changed the percentages of immune cells. In vivo, OMT prolonged survival time, alleviated pathological damages, and modulated immune cell infiltration in the cardiac allografts.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2021)
Article
Immunology
Saidou Balam, Simone Buchtler, Frederike Winter, Kathrin Schmidbauer, Sophia Neumayer, Yvonne Talke, Kerstin Renner, Edward K. Geissler, Matthias Mack
Summary: This study found that fibrosis, a prominent feature of chronic allograft rejection, is primarily driven by tissue-resident cells from the donor that produce collagen-1. Specifically, hematopoietic tissue-resident cells in the donor heart contribute significantly to graft fibrosis. In contrast, recipient-derived infiltrating cells and tissue-resident macrophages do not play a major role in collagen production.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Engineering, Multidisciplinary
Jan Lerut, Samuele Iesari
Summary: Perfect surgical techniques and adequate immunosuppression are crucial for graft and patient survival in liver transplantation. The current standard immunosuppression regimen is a triple-drug combination of a calcineurin inhibitor, antimetabolites, and short-term steroids. However, the optimal immunosuppression regimen is still unclear due to diverse study designs and changing definitions of rejection. Future trials should consider multiple endpoints and comprehensive evaluation of patient and graft survival, acute and chronic rejection, and long-term side effects.
Review
Pharmacology & Pharmacy
Min Young Kim, Daniel C. Brennan
Summary: Significant progress has been made in the pathophysiology, diagnosis, and treatment of antibody-mediated rejection (ABMR) in recent decades, but effective treatment for chronic ABMR remains a challenge. Chronic ABMR has a distinct phenotype from active ABMR and is mainly caused by de novo donor specific antibodies (DSA), leading to progressive graft injury.
FRONTIERS IN PHARMACOLOGY
(2021)
Article
Immunology
Alda Saldan, Carlo Mengoli, Dino Sgarabotto, Marny Fedrigo, Annalisa Angelini, Giuseppe Feltrin, Antonio Gambino, Gino Gerosa, Luisa Barzon, Davide Abate
Summary: This study found an association between CMV and EBV infections and early-onset AMR, suggesting these viral infections as relevant risk factors.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Gastroenterology & Hepatology
Tiong Y. Lim, Elena Perpinan, Maria-Carlota Londono, Rosa Miquel, Paula Ruiz, Ada S. Kurt, Elisavet Kodela, Amy R. Cross, Claudia Berlin, Joanna Hester, Fadi Issa, Abdel Douiri, Felix H. Volmer, Richard Taubert, Evangelia Williams, Anthony J. Demetris, Andrew Lesniak, Gilbert Bensimon, Juan Jose Lozano, Marc Martinez-Llordella, Tim Tree, Alberto Sanchez-Fueyo
Summary: This study investigated the role of low-dose IL-2 (LDIL-2) in maintaining liver allograft tolerance. The results showed that LDIL-2 expanded circulating regulatory T cells (Tregs) but failed to effectively suppress antigen-specific immune responses and promote the accumulation of intrahepatic Tregs. Furthermore, LDIL-2 induced a liver transcriptional response even before immunosuppression weaning. The study was terminated after the first 6 participants failed to reach the primary endpoint, requiring reinstitution of immunosuppression.
JOURNAL OF HEPATOLOGY
(2023)
Article
Immunology
Yi Chen, Wenmin Zhang, Hui Bao, Wubing He, Lihong Chen
Summary: The study found that HMGB1 expression is upregulated in liver allografts during acute rejection, leading to increased inflammatory cell infiltration and DC maturation, ultimately promoting T cell proliferation and differentiation. Inhibition of HMGB1 with glycyrrhizic acid during liver preservation was shown to reduce inflammation, hepatocyte damage, and prolong allograft survival time, suggesting a potential therapeutic target to prevent acute rejection in liver transplantation.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Surgery
Annelies E. de Weerd, Zainab Al Fatly, Marieken Boer-Verschragen, Judith A. Kal-van Gestel, Dave L. Roelen, Marjolein Dieterich, Michiel G. H. Betjes
Summary: This randomized-controlled pilot study evaluated the feasibility and safety of tacrolimus monotherapy in immunologically low-risk kidney transplant recipients. The results suggest that tacrolimus monotherapy may be safe and effective in reducing infections in these patients.
TRANSPLANT INTERNATIONAL
(2022)
Article
Urology & Nephrology
Ankita Patel, Tara Shertel, Michael Wynd, Vikram Wadhera, David Serur, Benjamin Schleich, Yuriy Yushkov, Michael Goldstein
Summary: A retrospective observational study was conducted on 37 kidney transplant recipients using the DNB protocol for maintenance immunosuppression in lymphocyte-depleted setting. Results showed a high patient survival and graft survival rate at one year, with complications such as DGF and acute cellular rejection.